作者：
David S,Hong [1]
;
Marcus O,Butler [2]
;
Russell K,Pachynski [3]
;
Ryan,Sullivan [4]
;
Partow,Kebriaei [1]
;
Sarah,Boross-Harmer [2]
;
Armin,Ghobadi [3]
;
Matthew J,Frigault [4]
;
Ecaterina E,Dumbrava [1]
;
Amy,Sauer [5]
;
Francine,Brophy [5]
;
Jean-Marc,Navenot [5]
;
Svetlana,Fayngerts [5]
;
Zohar,Wolchinsky [6]
;
Robyn,Broad [6]
;
Dzmitry G,Batrakou [5]
;
Ruoxi,Wang [6]
;
Luisa M,Solis [1]
;
Dzifa Yawa,Duose [1]
;
Joseph P,Sanderson [6]
;
Andrew B,Gerry [6]
;
Diane,Marks [5]
;
Jane,Bai [5]
;
Elliot,Norry [5]
;
Paula M,Fracasso [5]
作者单位：
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
[1]
Princess Margaret Hospital Cancer Centre, University of Toronto, Toronto, ON, Canada.
[2]
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
[3]
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
[4]
Adaptimmune LLC, Philadelphia, PA, United States.
[5]
Adaptimmune Limited, Abingdon, United Kingdom.
[6]
DOI
10.3389/fonc.2022.818679
PMID
35372008
发布时间
2022-04-05
换一批
换一批
